{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:48:50Z","timestamp":1794203330366,"version":"4.8.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070927"],"award-info":[{"award-number":["32070927"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MC121"],"award-info":[{"award-number":["ZR2023MC121"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011482","name":"Yantai Science and Technology Bureau","doi-asserted-by":"publisher","award":["ZR2025LQ022"],"award-info":[{"award-number":["ZR2025LQ022"]}],"id":[{"id":"10.13039\/501100011482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"DOI":"10.1038\/s41434-026-00621-5","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:33:00Z","timestamp":1779726780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Research progress and development strategies of antibody-oligonucleotide conjugates"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4456-3016","authenticated-orcid":false,"given":"Wenshuang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109\u2013118.","journal-title":"Nucleic Acid Ther"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28:1759\u20131771.","journal-title":"Mol Ther"},{"key":"621_CR3","doi-asserted-by":"crossref","unstructured":"Wu X, Liu S, Liu D, Li X, Wang H, Han X. Global and Chinese trends in oligonucleotide drug clinical development: a comparative analysis. Pharmacol Res. 2024;210:107487.","DOI":"10.1016\/j.phrs.2024.107487"},{"key":"621_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1260921","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharm. 2023;14:1260921.","journal-title":"Front Pharm"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u20131519.","journal-title":"N Engl J Med"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/17425247.2025.2466767","volume":"22","author":"Z-X Qin","year":"2025","unstructured":"Qin Z-X, Zuo L, Zeng Z, Ma R, Xie W, Zhu X, et al. GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases. Expert Opin Drug Deliv. 2025;22:455\u2013469.","journal-title":"Expert Opin Drug Deliv"},{"key":"621_CR7","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.cell.2023.07.017","volume":"186","author":"E Kaffe","year":"2023","unstructured":"Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, et al. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell. 2023;186:3793\u20133809.e26.","journal-title":"Cell"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova B, Burke RS, Cochran M, Hood MD, Johns R, Kovach PR, et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 2023;51:5901\u20135910.","journal-title":"Nucleic Acids Res"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"E Song","year":"2005","unstructured":"Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709\u201317.","journal-title":"Nat Biotechnol"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/nar\/gku1362","volume":"43","author":"TL Cuellar","year":"2015","unstructured":"Cuellar TL, Barnes D, Nelson C, Tanguay J, Yu SF, Wen X, et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 2015;43:1189\u2013203.","journal-title":"Nucleic Acids Res"},{"key":"621_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.","journal-title":"Nat Commun"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1002\/anie.201800860","volume":"57","author":"C Zhang","year":"2018","unstructured":"Zhang C, Dai P, Vinogradov AA, Gates ZP, Pentelute BL. Site-Selective Cysteine\u2013Cyclooctyne Conjugation. Angew Chem Int Ed. 2018;57:6459\u20136463.","journal-title":"Angew Chem Int Ed"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.omtn.2017.10.003","volume":"9","author":"X Song","year":"2017","unstructured":"Song X, Wang X, Ma Y, Liang Z, Yang Z, Cao H. Site-Specific Modification Using the 2\u2032-Methoxyethyl Group Improves the Specificity and Activity of siRNAs. Mol Ther - Nucleic Acids. 2017;9:242\u2013250.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"621_CR14","unstructured":"Geall AJ, Doppalapudi VR, Chu DS-H, Cochran MC, Hood M, Darimont BD, et al. Compositions and methods of treating muscle atrophy and myotonic dystrophy. PubChem Patent Summary for US-10881743-B2."},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673\u2013694.","journal-title":"Nat Rev Drug Discov"},{"key":"621_CR16","doi-asserted-by":"crossref","unstructured":"Meng Q, Yang M, Xing F, Xie Z, Hao Y, Jiang P, et al. Antibody-oligonucleotide conjugates in cancer therapy: potential and promise. Crit Rev Oncol\/Hematol. 2025;215:104858.","DOI":"10.1016\/j.critrevonc.2025.104858"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021;11:3889\u20133907.","journal-title":"Acta Pharm Sin B"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","volume":"16","author":"JJ Rennick","year":"2021","unstructured":"Rennick JJ, Johnston APR, Parton RG. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol. 2021;16:266\u2013276.","journal-title":"Nat Nanotechnol"},{"key":"621_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.607692","volume":"12","author":"PV Candelaria","year":"2021","unstructured":"Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. Front Immunol. 2021;12:607692.","journal-title":"Front Immunol"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.biocel.2004.02.007","volume":"36","author":"P Aisen","year":"2004","unstructured":"Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004;36:2137\u20132143.","journal-title":"Int J Biochem Cell Biol"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1212\/WNL.98.18_supplement.1761","volume":"98","author":"U Etxaniz","year":"2022","unstructured":"Etxaniz U, Diaz M, Bhardwaj R, Tyaglo O, Lemoine K, Missinato MA, et al. Antibody-oligonucleotide conjugates (AOCs) demonstrate potent and durable exon skipping and dystrophin restoration in a mouse model of duchenne muscular dystrophy (S23.003). Neurology. 2022;98:1761.","journal-title":"Neurology"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.nmd.2023.07.147","volume":"33","author":"M Girgenrath","year":"2023","unstructured":"Girgenrath M, Estrella N, Kumar A, Li J, Hicks A, Brennan C, et al. P20 Endosomal Escape Vehicles (EEV\u2122) - Oligonucleotides conjugates produce exon skipping and dystrophin production in preclinical models of Duchenne muscular dystrophy. Neuromuscul Disord. 2023;33:S102.","journal-title":"Neuromuscul Disord"},{"key":"621_CR23","unstructured":"Alam R, Alvarado A, Andrews FH, Babb NA, Balasubramaniam D, Chauvigne-Hines L, et al. Transferrin receptor binding proteins and conjugates. Publication Number WO\/2024\/036096."},{"key":"621_CR24","doi-asserted-by":"crossref","unstructured":"Lee HN, Jeong MS, Jang SB. Molecular characteristics of amyloid precursor protein (APP) and its effects in cancer. Int J Mol Sci. 2021;22:4999.","DOI":"10.3390\/ijms22094999"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tibtech.2020.07.003","volume":"39","author":"RE Gordon","year":"2021","unstructured":"Gordon RE, Nemeth JF, Singh S, Lingham RB, Grewal IS. Harnessing SLE autoantibodies for intracellular delivery of biologic therapeutics. Trends Biotechnol. 2021;39:298\u2013310.","journal-title":"Trends Biotechnol"},{"key":"621_CR26","doi-asserted-by":"crossref","unstructured":"Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, et al. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight. 2021;6:e145875.","DOI":"10.1172\/jci.insight.145875"},{"key":"621_CR27","doi-asserted-by":"crossref","unstructured":"Naes SM, Ab-Rahim S, Mazlan M, Abdul Rahman A, Zhang DM. Equilibrative nucleoside transporter 2: properties and physiological roles. BioMed Res Int. 2020;2020:5197626.","DOI":"10.1155\/2020\/5197626"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0169-328X(99)00164-3","volume":"70","author":"CM Anderson","year":"1999","unstructured":"Anderson CM, Baldwin SA, Young JD, Cass CE, Parkinson FE. Distribution of mRNA encoding a nitrobenzylthioinosine-insensitive nucleoside transporter (ENT2) in rat brain. Brain Res Mol Brain Res. 1999;70:293\u20137.","journal-title":"Brain Res Mol Brain Res"},{"key":"621_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2594260","volume":"17","author":"T Manso","year":"2025","unstructured":"Manso T, Sanou G, Nousias C, Maalem I, Boutin F, Giudicelli V, et al. Identification of engineered IMGT Fc variants in IMGT\/mAb-DB, a database of therapeutic antibodies and fusion proteins. MAbs. 2025;17:2594260.","journal-title":"MAbs"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.18632\/oncotarget.28651","volume":"15","author":"M Rackear","year":"2024","unstructured":"Rackear M, Quijano E, Ianniello Z, Col\u00f3n-R\u00edos DA, Krysztofiak A, Abdullah R, et al. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget. 2024;15:699\u2013713.","journal-title":"Oncotarget"},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/hep.23847","volume":"52","author":"CF Chen","year":"2010","unstructured":"Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, Lin CH, et al. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology. 2010;52:1690\u2013701.","journal-title":"Hepatology"},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ijc.20524","volume":"112","author":"X Farr\u00e9","year":"2004","unstructured":"Farr\u00e9 X, Guill\u00e9n-G\u00f3mez E, S\u00e1nchez L, Hardisson D, Plaza Y, Lloberas J, et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer. 2004;112:959\u201366.","journal-title":"Int J Cancer"},{"key":"621_CR33","doi-asserted-by":"crossref","unstructured":"Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction Targeted Therapy. 2025;10:227.","DOI":"10.1038\/s41392-025-02280-1"},{"key":"621_CR34","doi-asserted-by":"crossref","unstructured":"Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers. 2020;12:303.","DOI":"10.3390\/cancers12020303"},{"key":"621_CR35","doi-asserted-by":"crossref","unstructured":"Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021;22:2150.","DOI":"10.3390\/ijms22042150"},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u2013395.","journal-title":"Annu Rev Immunol"},{"key":"621_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S136575","volume":"ume 9","author":"N Uy","year":"2018","unstructured":"Uy N, Nadeau Nguyen M, Stahl M, Zeidan A. Inotuzumab ozogamicin in the treatment of relapsed\/refractory acute B cell lymphoblastic leukemia. J Blood Med. 2018;9:67\u201374.","journal-title":"J Blood Med"},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imm.12290","volume":"143","author":"LS Kwong","year":"2014","unstructured":"Kwong LS, Brown MH, Barclay AN, Hatherley D. Signal-regulatory protein \u03b1 from the NOD mouse binds human CD47 with an exceptionally high affinity \u2013 implications for engraftment of human cells. Immunology. 2014;143:61\u201367.","journal-title":"Immunology"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, et al. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13:96.","journal-title":"J Hematol Oncol"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41375-022-01805-9","volume":"37","author":"J Yu","year":"2023","unstructured":"Yu J, Li S, Chen D, Liu D, Guo H, Yang C, et al. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRP\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRP\u03b1 interaction and Fc\u0263R engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia. 2023;37:695\u2013698.","journal-title":"Leukemia"},{"key":"621_CR41","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Investig. 2016;126:2610\u20132620.","journal-title":"J Clin Investig"},{"key":"621_CR42","doi-asserted-by":"crossref","unstructured":"Roberts DD, Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, et al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. Plos One. 2016;11:e0153550.","DOI":"10.1371\/journal.pone.0153550"},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2020","unstructured":"Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109:74\u2013103.","journal-title":"J Pharm Sci"},{"key":"621_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146:467\u2013478.","journal-title":"J Allergy Clin Immunol"},{"key":"621_CR45","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","volume":"11","author":"BC Mackness","year":"2019","unstructured":"Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs. 2019;11:1276\u20131288.","journal-title":"mAbs"},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s11095-017-2219-y","volume":"34","author":"Z Li","year":"2017","unstructured":"Li Z, Krippendorff BF, Shah DK. Influence of Molecular size on the clearance of antibody fragments. Pharm Res. 2017;34:2131\u20132141.","journal-title":"Pharm Res"},{"key":"621_CR47","doi-asserted-by":"crossref","unstructured":"Xu R, Zheng Y, Tai W. A single-chain fab derived drug conjugate for HER2 specific delivery. Biomaterials. 2025;313:122798.","DOI":"10.1016\/j.biomaterials.2024.122798"},{"key":"621_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody\u2013drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u2013661.","journal-title":"Nat Rev Drug Discov"},{"key":"621_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddtec.2018.10.005","volume":"30","author":"DA Richards","year":"2018","unstructured":"Richards DA. Exploring alternative antibody scaffolds: antibody fragments and antibody mimics for targeted drug delivery. Drug Discov Today Technol. 2018;30:35\u201346.","journal-title":"Drug Discov Today Technol"},{"key":"621_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2592422","volume":"17","author":"BA Smith","year":"2025","unstructured":"Smith BA, Meeks CB, Murray-Brown I, McCarthy EA, Julian MC, Arndt J, et al. Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics. MAbs. 2025;17:2592422.","journal-title":"MAbs"},{"key":"621_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40259-022-00573-3","volume":"37","author":"D M\u00fcller","year":"2023","unstructured":"M\u00fcller D. Targeting co-stimulatory receptors of the TNF superfamily for cancer immunotherapy. BioDrugs. 2023;37:21\u201333.","journal-title":"BioDrugs"},{"key":"621_CR52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-022-05673-2","volume":"614","author":"X Yu","year":"2023","unstructured":"Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 2023;614:539\u2013547.","journal-title":"Nature"},{"key":"621_CR53","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23:1929\u20131936.","journal-title":"Clin Cancer Res"},{"key":"621_CR54","doi-asserted-by":"crossref","unstructured":"Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, et al. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024;15:2007.","DOI":"10.1038\/s41467-024-46321-9"},{"key":"621_CR55","doi-asserted-by":"crossref","unstructured":"\u00d8stergaard ME, Carrer M, Anderson BA, Afetian M, Bakooshli Mohsen A, Santos JA, et al. Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles. Nucleic Acids Res. 2025;53:gkaf270.","DOI":"10.1093\/nar\/gkaf270"},{"key":"621_CR56","doi-asserted-by":"crossref","unstructured":"Brennan FR, Polli JR, Sathish J, Ramones M, Wolf B, Schlothauer T, et al. Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies. mAbs. 2025;17:2505092.","DOI":"10.1080\/19420862.2025.2505092"},{"key":"621_CR57","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","volume":"30","author":"I Dovgan","year":"2019","unstructured":"Dovgan I, Koniev O, Kolodych S, Wagner A. Antibody\u2013oligonucleotide conjugates as therapeutic, imaging, and detection agents. Bioconjugate Chem. 2019;30:2483\u20132501.","journal-title":"Bioconjugate Chem"},{"key":"621_CR58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.bbrc.2018.01.139","volume":"496","author":"Z Rattray","year":"2018","unstructured":"Rattray Z, Dubljevic V, Rattray NJW, Greenwood DL, Johnson CH, Campbell JA, et al. Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications. Biochem Biophys Res Commun. 2018;496:858\u2013864.","journal-title":"Biochem Biophys Res Commun"},{"key":"621_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202415272","volume":"64","author":"L Zhou","year":"2025","unstructured":"Zhou L, Bi J, Chang S, Bai Z, Yu J, Wang R, et al. Self-Assembled Antibody-Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides. Angew Chem Int Ed Engl. 2025;64:e202415272.","journal-title":"Angew Chem Int Ed Engl"},{"key":"621_CR60","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","volume":"26","author":"R van Geel","year":"2015","unstructured":"van Geel R, Wijdeven MA, Heesbeen R, Verkade JMM, Wasiel AA, van Berkel SS, et al. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody\u2013drug conjugates. Bioconjugate Chem. 2015;26:2233\u20132242.","journal-title":"Bioconjugate Chem"},{"key":"621_CR61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard A. Antibody-oligonucleotide conjugates enter the clinic. Nat Rev Drug Discov. 2022;21:6\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"621_CR62","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48:4361\u20134374.","journal-title":"Chem Soc Rev"},{"key":"621_CR63","unstructured":"Subramanian RR, Qatanani MT, Weeden T, Desjardins CA. Muscle targeting complexes and uses thereof for treating myotonic dystrophy. PubChem Patent Summary for US-2024148891-A1."},{"key":"621_CR64","unstructured":"Desjardins CA, Tang K, Beskrovnaya O, Davis J, Mix C, Weeden T et al. Dosing Of Muscle Targeting Complexes For Treating Dystrophinopathies. PubChem Patent Summary for US-2025018050-A1."},{"key":"621_CR65","unstructured":"Subramanian RR, Qatanani MT, Weeden T, Desjardins CA, Quinn B, Najim J. Muscle targeting complexes and uses thereof for skipping exon 45 OF A DMD GENE. Publication Number WO\/2024\/097644."},{"key":"621_CR66","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1021\/acs.bioconjchem.7b00785","volume":"29","author":"D Su","year":"2018","unstructured":"Su D, Kozak KR, Sadowsky J, Yu S-F, Fourie-O\u2019Donohue A, Nelson C, et al. Modulating antibody\u2013drug conjugate payload metabolism by conjugation site and linker modification. Bioconjugate Chem. 2018;29:1155\u20131167.","journal-title":"Bioconjugate Chem"},{"key":"621_CR67","unstructured":"Hofer K, Mans\u00f8 M, Martin RE, Mohamed MYH, Oelschlaegel T, Ravn J, et al. Linkers for site-specific antibody conjugation. Publication Number WO 2024\/017923 A1."},{"key":"621_CR68","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","volume":"67","author":"M Cochran","year":"2024","unstructured":"Cochran M, Arias D, Burke R, Chu D, Erdogan G, Hood M, et al. Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-siRNA conjugates for drug development. J Med Chem. 2024;67:14852\u201314867.","journal-title":"J Med Chem"},{"key":"621_CR69","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1093\/nar\/gkx818","volume":"45","author":"JK Nair","year":"2017","unstructured":"Nair JK, Attarwala H, Sehgal A, Wang Q, Aluri K, Zhang X, et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 2017;45:10969\u201310977.","journal-title":"Nucleic Acids Res"},{"key":"621_CR70","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","volume":"48","author":"CR Brown","year":"2020","unstructured":"Brown CR, Gupta S, Qin J, Racie T, He G, Lentini S, et al. Investigating the pharmacodynamic durability of GalNAc\u2013siRNA conjugates. Nucleic Acids Res. 2020;48:11827\u201311844.","journal-title":"Nucleic Acids Res"},{"key":"621_CR71","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1021\/jacs.7b02694","volume":"139","author":"MK Schlegel","year":"2017","unstructured":"Schlegel MK, Foster DJ, Kel\u2019in AV, Zlatev I, Bisbe A, Jayaraman M, et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc. 2017;139:8537\u20138546.","journal-title":"J Am Chem Soc"},{"key":"621_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117752","volume":"254","author":"P Li","year":"2020","unstructured":"Li P, Zhang J, Jia Y, Zhang Y. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies. Life Sci. 2020;254:117752.","journal-title":"Life Sci"},{"key":"621_CR73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u2013321.","journal-title":"Annu Rev Med"},{"key":"621_CR74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"621_CR75","first-page":"417","volume":"52","author":"J Wang","year":"2023","unstructured":"Wang J, Tan M, Wang Y, Liu X, Lin A. Advances in modification and delivery of nucleic acid drugs. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:417\u2013428.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"621_CR76","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.","journal-title":"Signal Transduct Target Ther"},{"key":"621_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154-155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154-155:163\u2013175.","journal-title":"Adv Drug Deliv Rev"},{"key":"621_CR78","doi-asserted-by":"crossref","unstructured":"Liu M, Li J, Zhao D, Yan N, Zhang H, Liu M, et al. Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Biomaterials. 2022;283:121415.","DOI":"10.1016\/j.biomaterials.2022.121415"},{"key":"621_CR79","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y. Safety and efficacy of 48-week pegylated interferon-\u03b1-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Front Med. 2024;11:1489671.","DOI":"10.3389\/fmed.2024.1489671"},{"key":"621_CR80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","volume":"80","author":"G Guan","year":"2024","unstructured":"Guan G, Zhang T, Ning J, Tao C, Gao N, Zeng Z, et al. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B. J Hepatol. 2024;80:41\u201352.","journal-title":"J Hepatol"},{"key":"621_CR81","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/09205063.2017.1422853","volume":"29","author":"K Hagiwara","year":"2018","unstructured":"Hagiwara K, Kurihara K, Honma M, Yamamoto J, Shinohara F. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect. J Biomater Sci, Polym Ed. 2018;29:448\u2013459.","journal-title":"J Biomater Sci, Polym Ed"},{"key":"621_CR82","doi-asserted-by":"crossref","unstructured":"Hawner M, Ducho C. Cellular targeting of oligonucleotides by conjugation with small molecules. Molecules. 2020;25:5963.","DOI":"10.3390\/molecules25245963"},{"key":"621_CR83","doi-asserted-by":"crossref","unstructured":"H\u00f6rberg J, Carlesso A, Reymer A. Mechanistic insights into ASO-RNA complexation: advancing antisense oligonucleotide design strategies. Mol Therapy - Nucleic Acids. 2024;35:102351.","DOI":"10.1016\/j.omtn.2024.102351"},{"key":"621_CR84","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","volume":"352","author":"T Ramasamy","year":"2022","unstructured":"Ramasamy T, Ruttala HB, Munusamy S, Chakraborty N, Kim JO. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Controlled Release. 2022;352:861\u2013878.","journal-title":"J Controlled Release"},{"key":"621_CR85","doi-asserted-by":"crossref","unstructured":"Nan Y, Zhang Y-J. Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds. Front Microbiol. 2018;9:750.","DOI":"10.3389\/fmicb.2018.00750"},{"key":"621_CR86","unstructured":"Eteplirsen. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012."},{"key":"621_CR87","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo YA. Golodirsen: first approval. Drugs. 2020;80:329\u2013333.","journal-title":"Drugs"},{"key":"621_CR88","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77:982\u2013991.","journal-title":"JAMA Neurol"},{"key":"621_CR89","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M. Casimersen: first approval. Drugs. 2021;81:875\u2013879.","journal-title":"Drugs"},{"key":"621_CR90","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"CA Desjardins","year":"2022","unstructured":"Desjardins CA, Yao M, Hall J, O\u2019Donnell E, Venkatesan R, Spring S, et al. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res. 2022;50:11401\u201311414.","journal-title":"Nucleic Acids Res"},{"key":"621_CR91","doi-asserted-by":"crossref","unstructured":"Etxaniz U, Marks I, Albin T, Diaz M, Bhardwaj R, Anderson A, et al. AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy. Nucleic Acids Res. 2025;53:gkaf241.","DOI":"10.1093\/nar\/gkaf241"},{"key":"621_CR92","doi-asserted-by":"crossref","unstructured":"Huo S, Li H, Boersma AJ, Herrmann A. DNA nanotechnology enters cell membranes. Adv Sci. 2019;6:1900043.","DOI":"10.1002\/advs.201900043"},{"key":"621_CR93","unstructured":"Wan HI, Bermingham CNWL. Methods of treating cancer using anti-Cd22 antibody oligonucleotide conjugates. PubChem Patent Summary for WO-2023225577-A1."},{"key":"621_CR94","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1023\/A:1016260110049","volume":"12","author":"I Walker","year":"1995","unstructured":"Walker I, Irwin WJ, Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res. 1995;12:1548\u201353.","journal-title":"Pharm Res"},{"key":"621_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85352-w","volume":"11","author":"V Lehot","year":"2021","unstructured":"Lehot V, Kuhn I, Nothisen M, Erb S, Kolodych S, Cianf\u00e9rani S, et al. Non-specific interactions of antibody-oligonucleotide conjugates with living cells. Sci Rep. 2021;11:5881.","journal-title":"Sci Rep"},{"key":"621_CR96","doi-asserted-by":"crossref","unstructured":"Heh E, Allen J, Ramirez F, Lovasz D, Fernandez L, Hogg T, et al. Peptide drug conjugates and their role in cancer therapy. Int J Mol Sci. 2023;24:829.","DOI":"10.3390\/ijms24010829"},{"key":"621_CR97","doi-asserted-by":"crossref","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225.","DOI":"10.1042\/BSR20150089"},{"key":"621_CR98","doi-asserted-by":"crossref","unstructured":"Lee HJ, Xie Y, Greineder CF, Tessier PM Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system. Adv Drug Delivery Rev. 2026;230:115778.","DOI":"10.1016\/j.addr.2026.115778"},{"key":"621_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.313","volume":"43","author":"M Oldham","year":"2024","unstructured":"Oldham M, Estrella N, Kumar A, Hicks A, Brennan C, Blake S, et al. 433P Therapeutic potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV\u2122) - Oligonucleotide Conjugate for the treatment of exon 44 skip amenable DMD. Neuromuscul Disord. 2024;43:104441.304.","journal-title":"Neuromuscul Disord"},{"key":"621_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.545","volume":"43","author":"J Larkindale","year":"2024","unstructured":"Larkindale J, Shoskes J, Garg B, Song G, Lonkar P, Babcock S, et al. 461P Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1. Neuromuscul Disord. 2024;43:104441.536.","journal-title":"Neuromuscul Disord"},{"key":"621_CR101","doi-asserted-by":"crossref","unstructured":"Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13:e13243.","DOI":"10.15252\/emmm.202013243"},{"key":"621_CR102","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat3386","volume":"4","author":"C \u00c4mm\u00e4l\u00e4","year":"2018","unstructured":"\u00c4mm\u00e4l\u00e4 C, Drury WJ, Knerr L, Ahlstedt I, Stillemark-Billton P, Wennberg-Huldt C, et al. Targeted delivery of antisense oligonucleotides to pancreatic \u03b2-cells. Sci Adv. 2018;4:eaat3386.","journal-title":"Sci Adv"},{"key":"621_CR103","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1021\/jacs.0c12043","volume":"143","author":"L Knerr","year":"2021","unstructured":"Knerr L, Prakash TP, Lee R, Drury Iii WJ, Nikan M, Fu W, et al. Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. J Am Chem Soc. 2021;143:3416\u20133429.","journal-title":"J Am Chem Soc"},{"key":"621_CR104","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630\u2013643.","journal-title":"Nat Nanotechnol"},{"key":"621_CR105","doi-asserted-by":"crossref","unstructured":"Klabenkova K, Fokina A, Stetsenko D. Chemistry of peptide-oligonucleotide conjugates: a review. Molecules. 2021;26:5420.","DOI":"10.3390\/molecules26175420"},{"key":"621_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105952","volume":"53","author":"A Paker","year":"2025","unstructured":"Paker A, Lochm\u00fcller H, Turner C, Nigim F, Larimer P, Johnson N. 386PA phase 1\/2 trial (Galileo Study) of VX-670 in adults with myotonic dystrophy type 1 (DM1): study design. Neuromuscul Disord. 2025;53:105952.","journal-title":"Neuromuscul Disord"},{"key":"621_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nat Med. 2025;31:45\u201359.","journal-title":"Nat Med"},{"key":"621_CR108","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1021\/acs.chemrev.4c00969","volume":"125","author":"Q Sun","year":"2025","unstructured":"Sun Q, Wang H, Xie J, Wang L, Mu J, Li J, et al. Computer-aided drug discovery for undruggable targets. Chem Rev. 2025;125:6309\u20136365.","journal-title":"Chem Rev"},{"key":"621_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13:45.","journal-title":"J Hematol Oncol"},{"key":"621_CR110","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14712598.2021.1880562","volume":"21","author":"M De Cecco","year":"2021","unstructured":"De Cecco M, Galbraith DN, McDermott LL. What makes a good antibody-drug conjugate? Expert Opin Biol Ther. 2021;21:841\u2013847.","journal-title":"Expert Opin Biol Ther"},{"key":"621_CR111","doi-asserted-by":"crossref","unstructured":"Li M, An H, Zhang J, Li W, Yu C, Wang L. Advances in the pharmaceutical development of antibody-oligonucleotide conjugates. Eur J Pharma Sci. 2025;215:107292.","DOI":"10.1016\/j.ejps.2025.107292"},{"key":"621_CR112","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res. 2015;32:3526\u201340.","journal-title":"Pharm Res"},{"key":"621_CR113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346.","journal-title":"Protein Cell"},{"key":"621_CR114","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1101\/gad.1210204","volume":"18","author":"K Okamura","year":"2004","unstructured":"Okamura K, Ishizuka A, Siomi H, Siomi MC. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 2004;18:1655\u201366.","journal-title":"Genes Dev"},{"key":"621_CR115","doi-asserted-by":"crossref","unstructured":"Shah MNA, Wilton-Clark H, Haque F, Powell B, Sutanto LE, Maradiya R, et al. DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function. Nat Commun. 2025;16:4477.","DOI":"10.1038\/s41467-025-59494-8"},{"key":"621_CR116","doi-asserted-by":"crossref","unstructured":"Zhang Z, Kuo JC, Yao S, Zhang C, Khan H, Lee RJ. CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials. Pharmaceutics. 2021;14:73.","DOI":"10.3390\/pharmaceutics14010073"},{"key":"621_CR117","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1039\/D3BM01970E","volume":"12","author":"M Li","year":"2024","unstructured":"Li M, Yao H, Yi K, Lao YH, Shao D, Tao Y. Emerging nanoparticle platforms for CpG oligonucleotide delivery. Biomater Sci. 2024;12:2203\u20132228.","journal-title":"Biomater Sci"},{"key":"621_CR118","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2147\/IJN.S435407","volume":"19","author":"QR Qi","year":"2024","unstructured":"Qi QR, Tian H, Yue BS, Zhai BT, Zhao F. Research progress of SN38 drug delivery system in cancer treatment. Int J Nanomed. 2024;19:945\u2013964.","journal-title":"Int J Nanomed"},{"key":"621_CR119","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","volume":"23","author":"KJ Norsworthy","year":"2018","unstructured":"Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23:1103\u20131108.","journal-title":"Oncologist"},{"key":"621_CR120","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518\u201348.","journal-title":"Nucleic Acids Res"},{"key":"621_CR121","doi-asserted-by":"crossref","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel). 2020;13:245.","DOI":"10.3390\/ph13090245"},{"key":"621_CR122","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41587-025-02987-0","volume":"44","author":"C Sheridan","year":"2026","unstructured":"Sheridan C. Now with oligos: antibody\u2013oligonucleotide conjugates are the new drug modality to watch. Nat Biotechnol. 2026;44:3\u20135.","journal-title":"Nat Biotechnol"},{"key":"621_CR123","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u2013337.","journal-title":"Nat Rev Drug Discov"},{"key":"621_CR124","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"621_CR125","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","volume":"64","author":"DG Brown","year":"2021","unstructured":"Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010\u20132019): trends and future directions. J Med Chem. 2021;64:2312\u20132338.","journal-title":"J Med Chem"},{"key":"621_CR126","doi-asserted-by":"crossref","unstructured":"Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, Junutula JR. Exploration of the antibody\u2013drug conjugate clinical landscape. mAbs. 2023;15:2229101.","DOI":"10.1080\/19420862.2023.2229101"},{"key":"621_CR127","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrrheum.2016.23","volume":"12","author":"PW Noble","year":"2016","unstructured":"Noble PW, Bernatsky S, Clarke AE, Isenberg DA, Ramsey-Goldman R, Hansen JE. DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nat Rev Rheumatol. 2016;12:429\u2013434.","journal-title":"Nat Rev Rheumatol"},{"key":"621_CR128","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette A, Chen J. SIRP\u03b1\u2013CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39:173\u2013184.","journal-title":"Trends Immunol"},{"key":"621_CR129","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265\u2013280.","journal-title":"Nat Rev Genet"},{"key":"621_CR130","unstructured":"Malecova B, Burke R, Darimont BD, SALA Cano D. Compositions and methods of treating facioscapulohumeral muscular dystrophy. PubChem Patent Summary for US-2023279395-A1."},{"key":"621_CR131","unstructured":"Ludwig DL, Pamarthy PBS, Ahmed RA, Bommireddy Venkata V, Quijano E, Glazer P. Antibody oligonucleotide conjugates. Publication Number WO\/2024\/158824."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00621-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T18:02:11Z","timestamp":1779732131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":131,"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00621-5","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}